Story perspectives

Boston Glaucoma Trial Uses Gene Reprogramming, Raises Safety Concerns

6/16/2026

Summary

Story summary

Researchers chose the eye because localized treatment carries fewer life-threatening risks than whole-body approaches.
Life Biosciences treated its first Boston glaucoma trial participant with three reprogramming genes to retinal cells.
The trial uses a viral vector and a doxycycline switch that can deactivate the genes, after a 2020 Harvard study restored vision in mice.
Scientists warn that hype could jeopardize research if safety problems such as cancer emerge.

1 of 1

Story summary

Researchers chose the eye because localized treatment carries fewer life-threatening risks than whole-body approaches.
Life Biosciences treated its first Boston glaucoma trial participant with three reprogramming genes to retinal cells.
The trial uses a viral vector and a doxycycline switch that can deactivate the genes, after a 2020 Harvard study restored vision in mice.
Scientists warn that hype could jeopardize research if safety problems such as cancer emerge.